| Line Item | 2024-12-31 | Y/Y |
|---|---|---|
| R&D Expense | $3.6M | +8.9% |
| SG&A Expense | $5.9M | -2.4% |
| Net Income | -$9.0M | -3.2% |
| Line Item | 2024-12-31 | Y/Y |
|---|---|---|
| Cash & Equivalents | $3.6M | +50.9% |
| Current Assets | $14.9M | +32.3% |
| Total Assets | $15.7M | +29.1% |
| Current Liabilities | $4.2M | +16.7% |
| Total Liabilities | $6.5M | -0.0% |
| Stockholders' Equity | $9.2M | +62.5% |
| Line Item | 2024-12-31 | Y/Y |
|---|---|---|
| Operating Cash Flow | -$7.9M | +0.1% |
| Investing Cash Flow | -$1.9M | -186.3% |
| Financing Cash Flow | $11.0M | +110.2% |